PMID- 35577101
OWN - NLM
STAT- MEDLINE
DCOM- 20220614
LR  - 20220822
IS  - 1872-7905 (Electronic)
IS  - 0022-1759 (Linking)
VI  - 506
DP  - 2022 Jul
TI  - Evaluation of cell-mediated immunity of E.coli nanovaccines in chickens.
PG  - 113280
LID - S0022-1759(22)00067-9 [pii]
LID - 10.1016/j.jim.2022.113280 [doi]
AB  - Nanovaccine is a revolutionary type of immunizations for various diseases that is 
      simple to manufacture and administer. As a result, we are working to develop 
      innovative nanovaccines against E. coli, which is capable of causing disease both 
      inside and outside of its predilection sites, causing respiratory and systemic 
      disease (colibacillosis).Colibacillosis is a global disease that significantly 
      affects poultry production. The present study aims to evaluate in vivo 
      cell-mediated immunity against a chitosan-nanovaccine from E. coli serogroups O1 
      and O78 to aid in limiting colibacillosis in chicken. Two hundred specific 
      pathogen-free (SPF) three weeks old broiler chickens were used and divided into 
      five groups: the first group inoculated with the outer membrane and flagellar 
      antigen (OF), the second group inoculated with chitosan capsulated-outer membrane 
      protein-flagellar antigen (CS(C)-O-F), the third group inoculated with chitosan 
      loaded-outer membrane protein-flagellar antigen (CS(L)-O-F), the fourth group was 
      vaccinated with (CS(L)-O-F-M) adjuvanted with Montanide ISA 71 RVG, and the fifth 
      group was left as unvaccinated control. The immune response was measured by 
      ELISA, lymphocyte proliferation test, and challenge test. The duration of 
      immunity was also studied. The CS(L)-O-F-M had the highest antibody titer in an 
      ELISA test using the O1 strain, and the CS(C)-O-F had the highest antibody titer 
      in an ELISA test using the O78 strain. For both O1 and O78 strains, the 
      CS(L)-O-F-M had the strongest cell-mediated immune response, which was validated 
      by the challenge test and duration study. We recommend producing nanovaccines 
      (CS(L)-O-F-M) from E.coli O1 and O78 strains as a new manufacturing vaccine based 
      on the demonstrated results. Because it produces highly effective humoral and 
      cell-mediated immune responses, this novel vaccine may be useful in reducing the 
      risk of colibacillosis.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Abd El-Aziz, Wafaa R
AU  - Abd El-Aziz WR
AD  - Department of Antigens and Sera Research, Veterinary Serum and Vaccine Research 
      Institute, Agricultural Research Center, Egypt.
FAU - Ibrahim, Hazem M
AU  - Ibrahim HM
AD  - Department of Antigens and Sera Research, Veterinary Serum and Vaccine Research 
      Institute, Agricultural Research Center, Egypt.
FAU - Elzorkany, Heba Elsayed
AU  - Elzorkany HE
AD  - Nanotechnology and Advanced Material Central Lab, Agricultural Research Center, 
      Giza, Egypt; Regional Center for Food and Feed, Agricultural Research Center, 
      Giza, Egypt.
FAU - Mohammed, Gina M
AU  - Mohammed GM
AD  - Central Laboratory for Evaluation of Veterinary Biologics, Agricultural Research 
      Center, Egypt.
FAU - Mikhael, Christine A
AU  - Mikhael CA
AD  - Central Laboratory for Evaluation of Veterinary Biologics, Agricultural Research 
      Center, Egypt.
FAU - Fathy, Nada A
AU  - Fathy NA
AD  - Department of Newcastle disease virus, Veterinary Serum and Vaccine Research 
      Institute, Agricultural Research center, Egypt.
FAU - Elshoky, Hisham A
AU  - Elshoky HA
AD  - Nanotechnology and Advanced Material Central Lab, Agricultural Research Center, 
      Giza, Egypt; Regional Center for Food and Feed, Agricultural Research Center, 
      Giza, Egypt. Electronic address: heshamalshoky@sci.cu.edu.eg.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220513
PL  - Netherlands
TA  - J Immunol Methods
JT  - Journal of immunological methods
JID - 1305440
RN  - 0 (Membrane Proteins)
RN  - 0 (Monatide (IMS 3015))
RN  - 8020-83-5 (Mineral Oil)
RN  - 9012-76-4 (Chitosan)
SB  - IM
MH  - Animals
MH  - Chickens
MH  - *Chitosan
MH  - Escherichia coli
MH  - *Escherichia coli Infections/prevention & control/veterinary
MH  - Immunity, Cellular
MH  - Membrane Proteins
MH  - Mineral Oil
MH  - *Poultry Diseases/prevention & control
OTO - NOTNLM
OT  - Cellular immunity
OT  - Chitosan nanoparticle
OT  - E.coli
OT  - Flagellar antigen
OT  - Outer membrane protein
EDAT- 2022/05/17 06:00
MHDA- 2022/06/15 06:00
CRDT- 2022/05/16 19:33
PHST- 2021/09/11 00:00 [received]
PHST- 2022/03/14 00:00 [revised]
PHST- 2022/05/10 00:00 [accepted]
PHST- 2022/05/17 06:00 [pubmed]
PHST- 2022/06/15 06:00 [medline]
PHST- 2022/05/16 19:33 [entrez]
AID - S0022-1759(22)00067-9 [pii]
AID - 10.1016/j.jim.2022.113280 [doi]
PST - ppublish
SO  - J Immunol Methods. 2022 Jul;506:113280. doi: 10.1016/j.jim.2022.113280. Epub 2022 
      May 13.